Westview Management dba Westview Investment Advisors purchased a new stake in Astrazeneca Plc (NYSE:AZN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 39,136 shares of the company's stock, valued at approximately $3,598,000. Astrazeneca accounts for approximately 1.7% of Westview Management dba Westview Investment Advisors' investment portfolio, making the stock its 23rd biggest position.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AZN. Cibc World Market Inc. grew its holdings in shares of Astrazeneca by 21.5% during the 3rd quarter. Cibc World Market Inc. now owns 64,421 shares of the company's stock valued at $4,942,000 after acquiring an additional 11,398 shares in the last quarter. TD Asset Management Inc increased its holdings in shares of Astrazeneca by 20.0% during the 3rd quarter. TD Asset Management Inc now owns 1,089,612 shares of the company's stock valued at $83,595,000 after acquiring an additional 181,273 shares during the last quarter. Y Intercept Hong Kong Ltd grew its holdings in Astrazeneca by 111.6% during the third quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company's stock valued at $5,113,000 after purchasing an additional 35,148 shares during the last quarter. AMG National Trust Bank boosted its holdings in shares of Astrazeneca by 20.4% during the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company's stock worth $3,298,000 after buying an additional 7,289 shares during the period. Finally, Oxbow Advisors LLC boosted its holdings in Astrazeneca by 96.2% during the third quarter. Oxbow Advisors LLC now owns 77,594 shares of the company's stock valued at $5,953,000 after acquiring an additional 38,043 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.
Astrazeneca Stock Performance
Astrazeneca stock opened at $183.40 on Monday. Astrazeneca Plc has a 1 year low of $122.48 and a 1 year high of $212.71. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72. The stock has a market cap of $284.44 billion, a PE ratio of 31.59, a P/E/G ratio of 1.38 and a beta of 0.32.
Astrazeneca Announces Dividend
The company also recently disclosed a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be given a $1.595 dividend. The ex-dividend date is Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca's dividend payout ratio is currently 66.26%.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on AZN shares. Deutsche Bank Aktiengesellschaft reaffirmed a "sell" rating on shares of Astrazeneca in a research report on Friday, February 6th. Morgan Stanley reissued an "overweight" rating and issued a $103.00 target price on shares of Astrazeneca in a report on Wednesday, December 3rd. TD Cowen reissued a "buy" rating on shares of Astrazeneca in a report on Wednesday. Weiss Ratings initiated coverage on Astrazeneca in a research report on Wednesday, March 11th. They issued a "buy (b)" rating for the company. Finally, Wall Street Zen upgraded shares of Astrazeneca from a "hold" rating to a "buy" rating in a research report on Friday. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $95.75.
Check Out Our Latest Stock Report on AZN
Astrazeneca Profile
(
Free Report)
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astrazeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrazeneca wasn't on the list.
While Astrazeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
